Dr. Michael T. Riebe Ph.D. serves as Independent Director of the Company. Dr. Riebe currently serves as a Vice President at AstraZeneca Pharmaceuticals, a position held since June 2016. Prior to joining AstraZeneca Pharmaceuticals, Dr. Riebe was employed by Pearl Therapeutics from January 2013 to June 2016, most recently as Senior Vice President. He also previously served as Vice President of Research and Development for iCeutica, Inc. from January 2012 to December 2012. Dr. Riebe received a B.A. in Chemistry from Kalamazoo College, and a Ph.D. from the University of Wisconsin Madison. Riebe’s experience as an officer of pharmaceutical and biopharmaceutical companies provides him with the qualifications and skills necessary to serve as a member of our Board.
As the Independent Director of Satsuma Pharmaceuticals, the total compensation of Michael Riebe at Satsuma Pharmaceuticals is $74,082. There are 7 executives at Satsuma Pharmaceuticals getting paid more, with John Kollins having the highest compensation of $1,368,100.
Michael Riebe is 59, he's been the Independent Director of Satsuma Pharmaceuticals since 2017. There are 3 older and 12 younger executives at Satsuma Pharmaceuticals. The oldest executive at Satsuma Pharmaceuticals, Inc. is Alan C. Mendelson J.D., 71, who is the Sec..
Over the last 5 years, insiders at Satsuma Pharmaceuticals have traded over $2,307,500 worth of Satsuma Pharmaceuticals stock and bought 63,855,812 units worth $106,923,937 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... a Nippon Biomedical Laborator.... On average, Satsuma Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $2,050,940. The most recent stock trade was executed by Ken Takanashi on 6 June 2023, trading 22,053,581 units of STSA stock currently worth $20,068,759.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals executives and other stock owners filed with the SEC include: